1. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis;Barkhof;Brain,1997
2. Update on inflammation, neurodegeneration, and immunoregulation in multiple sclerosis: therapeutic implications;Bennett;Clin Neuropharmacol,2009
3. Evolving views of MS pathogenesis;Cohen;Int J MS Care,2007
4. Comi G, Cook S, Giovannoni G, Rammohan K, Rieckmann P, Soelberg Sørensen P et al. Consistent MRI benefits with short-course cladribine tablets therapy across the range of patients with relapsing-remitting multiple sclerosis in the double-blind, placebo-controlled, 96-week CLARITY study (Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis [ECTRIMS], Gothenburg, Sweden, 13–16 October 2010 [Poster P403]. Poster presented at ECTRIMS 2010
5. Multiple sclerosis;Compston;Lancet,2008